Determining P-glycoprotein-drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers

Journal of Pharmacological and Toxicological Methods

Volumn 65, Issue 2, 2012, Pages 64-74

  Melchior, Donald L ^a   Sharom, Frances J ^b   Evers, Raymond ^c   Wright, George E ^a   Chu, Joseph W K ^b   Wright, Stephen E ^a   Chu, Xiaoyan ^c   Yabut, Jocelyn ^c  

^a GLSYNTHESIS INC   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ABCB1; Drug transport; Fluorescence; Inhibitor; Liposome; Polarized cell monolayer; Reconstitution

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIODARONE; CAPTOPRIL; CARVEDILOL; CYCLOSPORIN A; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; INDINAVIR; ISRADIPINE; IVERMECTIN; KETOCONAZOLE; LIPOSOME; MIBEFRADIL; NELFINAVIR; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PACLITAXEL; PROGESTERONE; QUINIDINE; RESERPINE; RITONAVIR; TAMOXIFEN; TARIQUIDAR; TELMISARTAN; TROGLITAZONE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL;

ARTICLE; BINDING AFFINITY; CELL LINE; CELL STRAIN LLC MDR1; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TRANSPORT; FLUORESCENCE; IC 50; INHIBITION KINETICS; MONOLAYER CULTURE; NONHUMAN; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TRANSPORT; SENSOR;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CRICETINAE; CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; LLC-PK1 CELLS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RECOMBINANT PROTEINS; SWINE;

CRICETINAE;

EID: 84859435363     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.02.002     Document Type: Article

References (38)

1. Acharya P., O'Connor M.P., Polli J.W., Ayrton A., Ellens H., Bentz J. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2008, 36:452-460.
2. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
3. Booth-Genthe C.L., Louie S.W., Carlini E.J., Li B., Leake B.F., Eisenhandler R., et al. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. Journal of Pharmacological and Toxicological Methods 2006, 54:78-89.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
5. Callaghan R., Ford R.C., Kerr I.D. The translocation mechanism of P-glycoprotein. FEBS Letters 2006, 580:1056-1063.
6. Chifflet S., Torriglia A., Chiesa R., Tolosa S. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Analytical Biochemistry 1988, 168:1-4.
7. Dickens D., Owen A., Alfirevic A., Pirmohamed M. Determination of the inhibitory potencies of p-glycoprotein inhibitors by transcellular permeability of Caco-2 cells. Proceedings of the British Pharmacological Society 2009, http://pa2online.org/abstracts/Vol7Issue4abst092P.pdf.
8. Eckford P.D., Sharom F.J. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochemistry and Cell Biology 2006, 84:1022-1033.
9. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chemical Reviews 2009, 109:2989-3011.
10. Feng B., Mills J.B., Davidson R.E., Mireles R.J., Janiszewski J.S., Troutman M.D., et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2008, 36:268-275.
11. Fenner K.S., Troutman M.D., Kempshall S., Cook J.A., Ware J.A., Smith D.A., et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clinical Pharmacology and Therapeutics 2009, 85:173-181.
12. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nature Reviews in Drug Discovery 2010, 9:215-236.
13. Höcheri, P. (2010). New tariquidar-like ABCB1 modulators in cancer chemotherapy: Preclinical pharmacokinetic/pharmacodynamic investigations and computational studies. Ph.D. Dissertation: Universität Regensburg.
14. Klinkhammer W., Muller H., Globisch C., Pajeva I.K., Wiese M. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorganic and Medicinal Chemistry 2009, 17:2524-2535.
15. 50) variability in various in vitro experimental systems. AAPS Workshop on Drug Transporters in ADME: from the Bench to the Bedside, Bethesda MD 2011.
16. Leslie E.M., Deeley R.G., Cole S.P.C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology 2005, 204:216-237.
17. Liu R., Sharom F.J. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 1996, 35:11865-11873.
18. Liu R., Siemiarczuk A., Sharom F.J. Intrinsic fluorescence of the P-glycoprotein multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry 2000, 39:14927-14938.
19. Loo T.W., Bartlett M.C., Clarke D.M. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. Journal of Biological Chemistry 2003, 278:39706-39710.
20. Lu P., Liu R., Sharom F.J. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. European Journal of Biochemistry 2001, 268:1687-1697.
21. Lugo M.R., Sharom F.J. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 2005, 44:14020-14029.
22. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Molecular Pharmacology 2000, 58:624-632.
23. Parveen Z., Stockner T., Bentele C., Pferschy S., Kraupp M., Freissmuth M., et al. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Molecular Pharmacology 2011, 79:443-452.
24. Polli J.W., Wring S.A., Humphreys J.E., Huang L.Y., Morgan J.B., Webster L.O., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. Journal of Pharmacology and Experimental Therapeutics 2001, 299:620-628.
25. Rautio J., Humphreys J.E., Webster L.O., Balakrishnan A., Keogh J.P., Kunta J.R., et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:786-792.
26. Reitman M.L., Chu X., Cai X., Yabut J., Venkatasubramanian R., Zajic S., et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clinical Pharmacology and Therapeutics 2011, 89:234-242.
27. Romsicki Y., Sharom F.J. Interaction of P-glycoprotein with defined phospholipid bilayers: a differential scanning calorimetric study. Biochemistry 1997, 36:9807-9815.
28. Romsicki Y., Sharom F.J. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 2001, 40:6937-6947.
29. Schinkel A.H. Pharmacological insights from P-glycoprotein knockout mice. International Journal of Clinical Pharmacology and Therapeutics 1998, 36:9-13.
30. Shapiro A.B., Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. European Journal of Biochemistry 1997, 250:130-137.
31. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs?. Journal of Membrane Biology 1997, 160:161-175.
32. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105-127.
33. Sharom F.J., Siarheyeva A. Functional assays for identification of compounds that interact with P-gp. Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment 2008, 261-290. Research Signpost, Trivandrum (India). N.A. Colabufo (Ed.).
34. Sharom F.J., Yu X., Doige C.A. Journal of Biological Chemistry 1993, 268:24197-24202.
35. Starling J.J., Shepard R.L., Cao J., Law K.L., Norman B.H., Kroin J.S., et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Advances in Enzyme Regulation 1997, 37:335-347.
36. U.S.Department of Health and Human Services Food and Drug Administration (FDA) Guidance for industry: Drug interaction studies - study design, data analysis, and implications for dosing and labelling 2006, [Electronic version], Available from:. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
37. Weiss J., Haefeli W.E. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:203-207.
38. Zolnerciks J.K., Booth-Genthe C.L., Gupta A., Harris J., Unadkat J.D. Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. Journal of Pharmaceutical Sciences 2011, 100:3055-3061.